Table 2.
Correlates of Cytomegalovirus Acquisition in HIV-1–Exposed but Uninfected Infants, Adjusted for Maternal HIV-1 RNA Level or CD4
| Models and Correlates | Adjusted HR (95% CI) | P Value |
|---|---|---|
| Model 1 | ||
| HIV-1 RNA level in plasma | 1.2 (.95–1.5) | .1 |
| CMV DNA level in breast milk | 1.4 (1.1–1.8) | .008 |
| Valacyclovira | 1.2 (.79–1.9) | .3 |
| Model 2 | ||
| CMV DNA level in breast milk | 1.4 (1.1–1.8) | .003 |
| CD4 count < 450 cells/mm3 | 1.6 (1.0–2.4) | .05 |
| Valacyclovira | 1.1 (.74–1.8) | .5 |
Model 1 was adjusted for week 2 plasma human immunodeficiency virus load. Model 2 was adjusted for baseline CD4 count at 32 weeks gestation. Both models include viral load measurements conducted at 2 weeks postpartum, excluding cases where infant cytomegalovirus was detected prior to 2 weeks.
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; HIV-1, human immunodeficiency virus type 1; HR, hazard ratio.
a Randomization to valacyclovir 500 mg twice daily.